Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024

Rhea-AI Summary

Mirum Pharmaceuticals, Inc. (MIRM) will report Q4 and year-end 2023 financial results on February 28, 2024, followed by a conference call to discuss financial results and corporate progress. Details for the call provided.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report fourth quarter and year-end 2023 financial results on Wednesday, February 28, 2024. Mirum will also host a conference call to discuss the fourth quarter and year-end 2023 financial results and recent corporate progress.

Conference call details:
Wednesday, February 28, 2024
4:30 p.m. ET / 1:30 p.m. PT

Dial-in:
U.S./Toll-Free: +1 833 470 1428
International: +1 404 975 4839
Passcode: 089049

You may also access the call via webcast by visiting the Events & Presentations section on Mirum’s website. A replay of this webcast will be available for 30 days.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, Cholbam® (cholic acid) capsules, and Chenodal® (chenodiol) tablets.

LIVMARLI, an IBAT inhibitor, is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in Canada. Mirum has also submitted LIVMARLI for approval in the U.S. in cholestatic pruritus in PFIC patients three months of age and older and in Europe in PFIC for patients two months of age and older. Cholbam is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme defects and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. Chenodal has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, Chenodal, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240221396043/en/

Media:

Erin Murphy

510-508-6521

media@mirumpharma.com

Investors:

Andrew McKibben

ir@mirumpharma.com

Sam Martin

Argot Partners

ir@mirumpharma.com

Source: Mirum Pharmaceuticals, Inc.

FAQ

When will Mirum Pharmaceuticals report its Q4 and year-end 2023 financial results?

Mirum Pharmaceuticals will report its Q4 and year-end 2023 financial results on Wednesday, February 28, 2024.

What time is the conference call to discuss the financial results scheduled for?

The conference call to discuss the financial results is scheduled for 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, February 28, 2024.

How can one access the conference call?

To access the conference call, you can dial U.S./Toll-Free: +1 833 470 1428 or International: +1 404 975 4839 with the Passcode: 089049. Alternatively, you can access the call via webcast on Mirum's website.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available for 30 days after the call.